PSTV Plus Therapeutics
- 1.6900
- +0.0250+1.50%
Plus Therapeutics News
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The
Express News | Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Express News | Plus Therapeutics Receives $3M Award Recommendation From The U.S. Department Of Defense
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced
Plus Therapeutics Announces Validation & Clinical Implementation Of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeningesCSF-01 testing is used as an expl
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Plus Therapeutics Faces Nasdaq Delisting Over Equity Shortfall
Plus Therapeutics CEO's Insightful Presentation Now Available
Express News | Plus Therapeutics Has Completed Dosing In Cohort 5 Of ReSPECT-LM Phase 1 Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases From Solid Tumors; Company Expects Moving Into Cohort 6 In Q2 2024 Following Standard Safety Review
Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials
Plus Therapeutics Is Worried About This – Should You Be Worried Too?
Q4 2023 Plus Therapeutics Inc Earnings Call
Earnings Call Summary | Plus Therapeutics(PSTV.US) Q4 2023 Earnings Conference
The following is a summary of the Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript:Financial Performance:Plus Therapeutics reported a decrease in cash reserves to $8.6 million by the en
Recap: Plus Therapeutics Q4 Earnings
Plus Therapeutics (NASDAQ:PSTV) reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsPlus Therapeutics beat estimate
Plus Therapeutics Q4 EPS $(0.70) Beats $(1.07) Estimate, Sales $1.31M Beat $1.06M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.07) by 34.58 percent. This is a 70.83 percent increase over losses of $(
Plus Therapeutics FY23 Loss $13.3M >PSTV
Plus Therapeutics FY23 Loss $13.3M >PSTV
Plus Therapeutics FY23 Loss/Shr $4.24 >PSTV
Plus Therapeutics FY23 Loss/Shr $4.24 >PSTV
Plus Therapeutics GAAP EPS of -$4.24 Misses by $3.07
Analysis
Price Target
No Data
